Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 29

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 29
---
present expenses for significant line items, including but not limited to, depreciation, amortization, and employee compensation. Entities
will also be required to provide a qualitative description of the amounts remaining in relevant expense captions that are not separately
disaggregated quantitatively, disclose the total amount of selling expenses and, in annual reporting periods, provide a definition of
what constitutes selling expenses. This pronouncement is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing this ASU to determine
the impact on its consolidated financial statements.

Management does not believe
that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s
consolidated financial statements.

<div align='center'>10</div>

NOTE 3 – BUSINESS COMBINATION

Business Combination Agreement
- On June 6, 2023, CERo Therapeutics, Inc. (“Predecessor”), which was incorporated in Delaware on September 23, 2016, and
based in South San Francisco, California, entered into the BCA with PBCE Merger Sub, Inc., a wholly-owned subsidiary of PBAX, and PBAX,
with the surviving operating entity being named CERo Therapeutics Holdings, Inc. (“Successor” or the “Company”),
and such transaction, the “Business Combination” or “Merger”.

The Company is focused on
genetically engineering human immune cells to fight cancer. The Predecessor focused on developing the CERo therapeutic platform and had
not yet begun clinical development or product commercialization. The Company’s efforts will focus on continued product development,
including clinical development, to support regulatory approval to commercialize and subsequent product commercialization.

The BCA was amended on February
5, 2024 and again on February 13, 2024. The Merger closed on February 14, 2024 (the “Closing”), at which time the following
occurred:

| 1. | The outstanding shares of Predecessor’s preferred stock were converted into 2,208 shares of Common Stock, par value $0.0001 per share (the “Common Stock”), valued at $21,635,926. |

| 2. | The outstanding shares of Predecessor’s common stock were converted into 292 shares of Common Stock, valued at $2,864